NCT06365853 2026-03-25A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionAbbViePhase 2 Recruiting100 enrolled